Blog
European-commission-issues-ce-mark-for-zeiss-cirrus-pathfinder-ai-tool

European Commission issues CE mark for Zeiss CIRRUS PathFinder AI tool

The clinical support system integrates artificial intelligence into OCT interpretation workflow

European Union flags outside the Berlaymont building in Brussels, Belgium, the headquarters of the European Commission. Concept image for ZEISS Medical Technology CE Mark CIRRUS PathFinder AI. Image credit: © olrat – stock.adobe.com

The all-in-one, AI-enhanced tool eliminates need for data exports or third-party platforms, according to Zeiss Medical Technology. Image credit: © olrat – stock.adobe.com

In a press release, Zeiss Medical Technology (Carl Zeiss Meditec AG) announced the European Commission has issued a CE mark for its CIRRUS PathFinder clinical support too. The CIRRUS PathFinder uses artificial intelligence (AI) technology to support imaging and the clinical workflow. According to the press release from the company, a proprietary deep learning algorithm accelerates optical coherence tomography (OCT) interpretation.1 Along with automatically identifying anomalous or abnormal OCT-B scans, a licensed element of the new CIRRUS software release, the platform also provides AI-enhanced OCT angiography (OCTA) image quality and multilayer segmentation.

Zeiss Medical Technology described1 the clinical applications of the Cirrus PathFinder platform, which “delivers high-speed image capture with HD imaging detail, a wide field of view, and AI decision support.” The all-in-one nature of the clinical support tool eliminates data exports or analysis with third-party platforms. The AI tool flags areas of concern during image acquisition, highlighting areas which may require more detailed follow-up imaging. Additionally, the software uses AI to enhance visualisation of the vascular structure. Enhanced layer segmentation and B-scan averaging of OCTA structural scans also provide more visibility into the structure of the eye.

Euan S. Thomson, PhD, head of the digital business unit for Zeiss Medical Technology, commented1 on the approval. “ZEISS is harnessing the power of data and artificial intelligence to deliver integrated digital solutions that are paving the way for the next era in ophthalmic care,” he said. “Our strategic focus on digitally connected workflows has placed us at the forefront for enabling ophthalmologists with powerful AI-driven capabilities, like those that have been fully integrated into Zeiss CIRRUS PathFinder.”

Magnus Reibenspiess, head of the ophthalmology strategic business unit at Zeiss Medical Technology, also provided comment.1 “The AI decision support capabilities of Zeiss CIRRUS PathFinder help enable faster, more informed and actionable diagnostics for a better clinical and patient experience,” he said.

The approval reflects an increased emphasis on AI-supported workflows and integrations at Zeiss Medical Technology. In May, the company introduced its new Zeiss Research Data Platform (ZEISS RDP), a cloud-based, AI-driven solution.2 Additionally, the Visumax 800 femtosecond laser with SMILE pro software received NMPA approval in China at the beginning of 2025.3 The surgical suite includes workflow enhancements such as VISULYZE nomograms for securely collecting and analysing patient data.

References

  1. ZEISS announces CE mark for CIRRUS PathFinder AI tool with automated OCT assessment. Press release. Carl Zeiss Meditec AG. Published August 21, 2025. Accessed August 21, 2025.
  2. Harp MD. ZEISS debuts Research Data Platform, highlights Boehringer Ingelheim partnership. Ophthalmology Times Europe. Published May 2, 2025. Accessed August 21, 2025. https://europe.ophthalmologytimes.com/view/zeiss-debuts-research-data-platform-highlights-boehringer-ingelheim-partnership
  3. Hayes H. Zeiss Visumax 800 with SMILE pro software receives NMPA approval in China. Ophthalmology Times Europe. Published February 26, 2025. Accessed August 21, 2025. https://europe.ophthalmologytimes.com/view/zeiss-visumax-800-with-smile-pro-software-receives-nmpa-approval-in-china

colind88

Related Posts

Artificial-intelligence-model-for-predicting-early-biochemical-recurrence-of-prostate-cancer-…
Artificial intelligence model for predicting early biochemical recurrence of prostate cancer …
Introduction Prostate cancer (PCa) is a major public health issue in developed countries1. Radical prostatectomy (RP) is associated with a lower incidence of disease progression than active monitoring2,3. However, one-third of patients experience biochemical recurrence (BCR) after the procedure4,5. Previous studies have shown that the survival rate of patients with BCR is 20% lower after
Fine-tune-openai-gpt-oss-models-using-amazon-sagemaker-hyperpod-recipes-–-aws
Fine-tune OpenAI GPT-OSS models using Amazon SageMaker HyperPod recipes – AWS
This post is the second part of the GPT-OSS series focusing on model customization with Amazon SageMaker AI. In Part 1, we demonstrated fine-tuning GPT-OSS models using open source Hugging Face libraries with SageMaker training jobs, which supports distributed multi-GPU and multi-node configurations, so you can spin up high-performance clusters on demand. In this post
Ai-that-finds-“shadows”-in-fusion-reactors-could-unlock-clean-energy-faster
AI That Finds “Shadows” in Fusion Reactors Could Unlock Clean Energy Faster
An artist’s interpretation of the inside of a fusion vessel, where some of the inner surfaces are directly exposed to the plasma. Some regions lie in the “magnetic shadow” of other components and are therefore magnetically shielded from the intense heat of the plasma. Credit: Kyle Palmer / PPPL Communications Department A new AI tool
Back To Top